In fact, FLT3 mutant AML cells treated with FLT3 inhibitors (AC220, quizartinib), activate an innate immune pathway via the interleukin-1 receptor-associated kinase 1 and 4 (IRAK1/4). Here, FLT3 is linked to acute myeloid leukemia.